Validation of New Virtual Reality Treatment for Children With Lazy Eye Using the Vedea Amblyopia Therapy (VAT)
NCT ID: NCT05620173
Last Updated: 2024-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
74 participants
INTERVENTIONAL
2023-02-22
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is to prove that the VAT is as effective or more effective than the current gold standard for treating children with lazy eye. This is occlusion therapy by patching the dominant eye.
Participants will play VR-games specifically designed for children with lazy eye for 30 minutes per day, 5 days per week for 16 weeks. This group of children will be compared to children that undergo regular occlusion therapy to see how both treatments options compare.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NEIVATECH Virtual Reality-based System for Amblyopia
NCT04819386
Novel Amblyopia Treatment With Virtual Reality Games
NCT06049459
Virtual Reality Game Playing in Amblyopia Therapy
NCT04261868
Patching or Gaming as Amblyopia Treatment?
NCT03767985
Early Detection and Prevention of Amblyopia and Visual Impairment Through Systematic Pediatric Vision Screening
NCT07112560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vedea Amblyopia Therapy (VAT) then Vedea Amblyopia Therapy
Children in this intervention arm will use the VAT for 16 weeks.
After the initial 16 weeks of treatment these children will be allowed to use the VAT for another 16 weeks.
Vedea Amblyopia Therapy (VAT)
Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
Occlusion therapy then Vedea Amblyopia Therapy (VAT)
Children in this intervention arm will adhere to a 'care as usual' regimen consisting of occlusion therapy as prescribed by their health care provider. They will do so for 16 weeks.
After the initial 16 weeks of treatment these children will crossover into the experimental arm to examine if they are still responsive to the VAT after already completing 16 weeks of traditional treatment.
Vedea Amblyopia Therapy (VAT)
Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
Occlusion therapy
Children are given an eye patch to occlude their dominant eye with for a prescribed number of hours per day. This may typically range anywhere between 2-8 hours per day, depending on the severity of the amblyopia.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vedea Amblyopia Therapy (VAT)
Children will use the VAT for 5 days per week, 30 minutes per day. They play VR-games using a VR-headset, which content is optimized for dichoptic training.
Occlusion therapy
Children are given an eye patch to occlude their dominant eye with for a prescribed number of hours per day. This may typically range anywhere between 2-8 hours per day, depending on the severity of the amblyopia.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with an unilateral anisometropic, strabismic and/or deprivation amblyopia.
Amblyopia was defined as an intraocular difference (IOD) in visual acuity (VA) of 0.2 log MAR (2 lines) or more. Angle of strabismus ≤ 10 prism diopters at near and distance fixation. Current clear media (in case of deprivation amblyopia after successful surgery).
* currently under treatment or starting treatment for unilateral amblyopia
* participants must have easy access to an Android device equal to or higher than a Samsung Galaxy S8
* written informed consent by parents or legal guardians
Exclusion Criteria
* documented history of severe negative side effects that occur with exposure to VR usage (eg. seizures or epileptic spasms)
* photosensitivity
* no developmental delay
* coexisting ocular pathology or systemic diseases
4 Years
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Health Holland
OTHER
Oogziekenhuis Rotterdam
OTHER
Rotterdams Oogheelkundig Instituut
UNKNOWN
Elisabeth-TweeSteden Ziekenhuis
OTHER
Jeroen Bosch Ziekenhuis
OTHER
Vedea Healthware BV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martha Tjon-Fo-Sang, PhD
Role: PRINCIPAL_INVESTIGATOR
The Rotterdam Eye Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, North Brabant, Netherlands
The Rotterdam Eye Hospital
Rotterdam, South Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Akizuki H, Uno A, Arai K, Morioka S, Ohyama S, Nishiike S, Tamura K, Takeda N. Effects of immersion in virtual reality on postural control. Neurosci Lett. 2005 Apr 29;379(1):23-6. doi: 10.1016/j.neulet.2004.12.041. Epub 2005 Jan 8.
Bailey IL, Lovie-Kitchin JE. Visual acuity testing. From the laboratory to the clinic. Vision Res. 2013 Sep 20;90:2-9. doi: 10.1016/j.visres.2013.05.004. Epub 2013 May 17.
Banks MS, Hoffman DM, Kim J, Wetzstein G. 3D Displays. Annu Rev Vis Sci. 2016 Oct 14;2:397-435. doi: 10.1146/annurev-vision-082114-035800. Epub 2016 Aug 15.
Birch EE, Li SL, Jost RM, Morale SE, De La Cruz A, Stager D Jr, Dao L, Stager DR Sr. Binocular iPad treatment for amblyopia in preschool children. J AAPOS. 2015 Feb;19(1):6-11. doi: 10.1016/j.jaapos.2014.09.009.
Black JM, Hess RF, Cooperstock JR, To L, Thompson B. The measurement and treatment of suppression in amblyopia. J Vis Exp. 2012 Dec 14;(70):e3927. doi: 10.3791/3927.
Coco-Martin MB, Pinero DP, Leal-Vega L, Hernandez-Rodriguez CJ, Adiego J, Molina-Martin A, de Fez D, Arenillas JF. The Potential of Virtual Reality for Inducing Neuroplasticity in Children with Amblyopia. J Ophthalmol. 2020 Jun 29;2020:7067846. doi: 10.1155/2020/7067846. eCollection 2020.
Feng J, Spence I, Pratt J. Playing an action video game reduces gender differences in spatial cognition. Psychol Sci. 2007 Oct;18(10):850-5. doi: 10.1111/j.1467-9280.2007.01990.x.
Foss AJ. Use of video games for the treatment of amblyopia. Curr Opin Ophthalmol. 2017 May;28(3):276-281. doi: 10.1097/ICU.0000000000000358.
Gao TY, Guo CX, Babu RJ, Black JM, Bobier WR, Chakraborty A, Dai S, Hess RF, Jenkins M, Jiang Y, Kearns LS, Kowal L, Lam CSY, Pang PCK, Parag V, Pieri R, Raveendren RN, South J, Staffieri SE, Wadham A, Walker N, Thompson B; BRAVO Study Team. Effectiveness of a Binocular Video Game vs Placebo Video Game for Improving Visual Functions in Older Children, Teenagers, and Adults With Amblyopia: A Randomized Clinical Trial. JAMA Ophthalmol. 2018 Feb 1;136(2):172-181. doi: 10.1001/jamaophthalmol.2017.6090.
Green CS, Bavelier D. Effect of action video games on the spatial distribution of visuospatial attention. J Exp Psychol Hum Percept Perform. 2006 Dec;32(6):1465-78. doi: 10.1037/0096-1523.32.6.1465.
Herbison N, Cobb S, Gregson R, Ash I, Eastgate R, Purdy J, Hepburn T, MacKeith D, Foss A; I-BiT study group. Interactive binocular treatment (I-BiT) for amblyopia: results of a pilot study of 3D shutter glasses system. Eye (Lond). 2013 Sep;27(9):1077-83. doi: 10.1038/eye.2013.113. Epub 2013 Jun 28.
Hess RF, Babu RJ, Clavagnier S, Black J, Bobier W, Thompson B. The iPod binocular home-based treatment for amblyopia in adults: efficacy and compliance. Clin Exp Optom. 2014 Sep;97(5):389-98. doi: 10.1111/cxo.12192. Epub 2014 Aug 18.
Holmes JM, Manh VM, Lazar EL, Beck RW, Birch EE, Kraker RT, Crouch ER, Erzurum SA, Khuddus N, Summers AI, Wallace DK; Pediatric Eye Disease Investigator Group. Effect of a Binocular iPad Game vs Part-time Patching in Children Aged 5 to 12 Years With Amblyopia: A Randomized Clinical Trial. JAMA Ophthalmol. 2016 Dec 1;134(12):1391-1400. doi: 10.1001/jamaophthalmol.2016.4262.
Kelly KR, Jost RM, Dao L, Beauchamp CL, Leffler JN, Birch EE. Binocular iPad Game vs Patching for Treatment of Amblyopia in Children: A Randomized Clinical Trial. JAMA Ophthalmol. 2016 Dec 1;134(12):1402-1408. doi: 10.1001/jamaophthalmol.2016.4224.
Levi DM. Rethinking amblyopia 2020. Vision Res. 2020 Nov;176:118-129. doi: 10.1016/j.visres.2020.07.014. Epub 2020 Aug 28.
Li R, Polat U, Makous W, Bavelier D. Enhancing the contrast sensitivity function through action video game training. Nat Neurosci. 2009 May;12(5):549-51. doi: 10.1038/nn.2296. Epub 2009 Mar 29.
Li SL, Jost RM, Morale SE, Stager DR, Dao L, Stager D, Birch EE. A binocular iPad treatment for amblyopic children. Eye (Lond). 2014 Oct;28(10):1246-53. doi: 10.1038/eye.2014.165. Epub 2014 Jul 25.
Li SL, Jost RM, Morale SE, De La Cruz A, Dao L, Stager D Jr, Birch EE. Binocular iPad treatment of amblyopia for lasting improvement of visual acuity. JAMA Ophthalmol. 2015 Apr;133(4):479-80. doi: 10.1001/jamaophthalmol.2014.5515. No abstract available.
Manh VM, Holmes JM, Lazar EL, Kraker RT, Wallace DK, Kulp MT, Galvin JA, Shah BK, Davis PL; Pediatric Eye Disease Investigator Group. A Randomized Trial of a Binocular iPad Game Versus Part-Time Patching in Children Aged 13 to 16 Years With Amblyopia. Am J Ophthalmol. 2018 Feb;186:104-115. doi: 10.1016/j.ajo.2017.11.017. Epub 2017 Nov 28.
Pang PCK, Lam CSY, Hess RF, Thompson B. Effect of dichoptic video game treatment on mild amblyopia - a pilot study. Acta Ophthalmol. 2021 May;99(3):e423-e432. doi: 10.1111/aos.14595. Epub 2020 Sep 30.
Tailor V, Ludden S, Bossi M, Bunce C, Greenwood JA, Dahlmann-Noor A. Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years. Cochrane Database Syst Rev. 2022 Feb 7;2(2):CD011347. doi: 10.1002/14651858.CD011347.pub3.
Tychsen L, Foeller P. Effects of Immersive Virtual Reality Headset Viewing on Young Children: Visuomotor Function, Postural Stability, and Motion Sickness. Am J Ophthalmol. 2020 Jan;209:151-159. doi: 10.1016/j.ajo.2019.07.020. Epub 2019 Aug 1.
Tychsen L, Thio LL. Concern of Photosensitive Seizures Evoked by 3D Video Displays or Virtual Reality Headsets in Children: Current Perspective. Eye Brain. 2020 Feb 11;12:45-48. doi: 10.2147/EB.S233195. eCollection 2020.
Xiao S, Angjeli E, Wu HC, Gaier ED, Gomez S, Travers DA, Binenbaum G, Langer R, Hunter DG, Repka MX; Luminopia Pivotal Trial Group. Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia. Ophthalmology. 2022 Jan;129(1):77-85. doi: 10.1016/j.ophtha.2021.09.001. Epub 2021 Sep 14.
Ziak P, Holm A, Halicka J, Mojzis P, Pinero DP. Amblyopia treatment of adults with dichoptic training using the virtual reality oculus rift head mounted display: preliminary results. BMC Ophthalmol. 2017 Jun 28;17(1):105. doi: 10.1186/s12886-017-0501-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL79107.000.22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.